1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Osang Healthcare Co. Ltd.

Osang Healthcare Co. Ltd.

KKRX:036220
5,570.00
KRW
-110.00
(-1.94%)
-322.57EPS
120.46BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,063.71
6,916.04
6,370.78
6,595.04
4,507.63
4,604.04
4,663.55
21,030.13
10,782.4
15,479.23
27,957.79
5,928.03
9,350.56
8,681.54
Basic EPS, GAAP
-1,076
-830
-1,063
-1,217
734
176
-344
10,190
119
3,245
9,148
-837
226
-322.29
Free Cash Flow per Basic Share
-1,813.45
-546.94
-184.74
95.49
-248.1
-70.35
280.19
7,597.77
74.06
2,431.13
9,169.79
-3,813.11
-930.24
-354.1
Dividend per Share
- -
- -
- -
- -
- -
- -
49.95
- -
1,999.1
1,987.47
1,991.6
1,853.69
498.38
- -
Book Value per Share
7,606.04
6,260.53
6,194.29
5,802.4
6,742.31
9,043.91
8,422.53
15,740.98
14,180.86
15,881.26
23,285.03
20,839.83
20,439.26
20,463.4
Tangible Book Value per Share
7,308.39
5,953.54
6,025.49
5,617.92
6,554.55
8,885.74
8,287.53
15,659.36
14,046.73
15,741.35
23,149.31
20,353.36
19,849.15
19,852.57
Basic Weighted Avg Shares
8
8
8
9
12
12
12
12
12
13
13
14
14
14
Sales/Revenue/Turnover
50,982
55,082
50,383
59,074
54,340
56,146
57,269
257,967
132,327
193,893
355,847
80,488
128,629
119,376
Operating Margin (%)
-12.45
-7.68
-0.91
7.53
-0.41
2.84
-2.64
62.31
-5.35
25.43
40.14
-30.52
1.89
-5.05
Depreciation Expense
2,322
2,580
2,494
2,243
2,436
2,520
2,603
2,673
3,956
5,413
6,335
7,156
7,866
8,131
Net Income, GAAP
-9,047
-6,610
-8,407
-10,901
8,848
2,146
-4,224
124,996
1,460
40,647
116,436
-11,364
3,109
-4,432
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
19.54
- -
21.56
23.47
- -
- -
- -
Profit Margin (%)
-17.74
-12
-16.69
-18.45
16.28
3.82
-7.38
48.45
1.1
20.96
32.72
-14.12
2.42
-3.71
Working Capital
12,214
14,537
23,487
12,272
15,424
33,053
30,806
139,513
104,386
109,260
158,507
54,255
77,586
60,520
LT Debt
4,776
20,232
13,789
- -
- -
- -
- -
- -
259
131
367
359
30,399
21,546
Total Equity
63,139
48,970
51,961
48,674
56,559
75,866
70,653
198,090
178,479
199,893
293,291
286,018
281,319
281,660
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
84.87
- -
22.82
46.9
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
87.69
- -
21.41
47.01
- -
- -
- -
Return on Common Equity (%)
-13.24
-11.79
-16.66
-21.66
16.82
3.24
-5.77
93.02
0.78
21.49
47.25
-3.93
1.1
-1.57

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5,415
13,906
27,021
LT Borrowings
41,545
30,238
20,698
LT Finance Leases
174
162
848
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
199,250
162,810
120,458

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
112,989
101,679
98,667
Cash, Cash Equivalents & STI
56,661
41,817
38,499
Accounts Receivable, Net
31,922
33,799
36,034
Inventories
21,456
21,113
20,734
Total Current Liabilities
15,873
24,094
38,147
Payables & Accruals
- -
- -
- -
ST Debt
5,415
13,906
27,021
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.22%
8.94%
-1.64%
Free Cash Flow
464.32%
643.01%
-75.28%
Net Income, GAAP
-104.93%
506.75%
-127.36%
Sales/Revenue/Turnover
42.88%
12.76%
59.81%
Total Cash Common Dividend
- -
- -
-72.76%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,684
19,998
20,432
19,374
80,488
2025
32,129
42,035
25,493
28,972
128,629
2026
22,876
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105
-450
-429
-103.16
-837
2025
288
-17.71
218.84
-261.77
226
2026
-261.56
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,853.69
2025
- -
- -
- -
- -
498.38
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Byungyeol Yoo
Full Time Employees
336
Sector
Health technology
Industry
Medical specialties
Address
132, Anyangcheondong-ro Anyang-si GY South Korea
IPO Date
Mar 13, 2024
Website
osanghc.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Osang Healthcare Co., Ltd. (036220.KQ) researches, develops, manufactures and sells in-vitro diagnostic (IVD) medical devices and biosensors specializing in point-of-care testing (POCT) solutions across biochemistry, immunoassay, molecular diagnostics and smart healthcare; core products include blood glucose monitors such as the GluNEO series (GluNEO H, GluNEO Dual, GluNEO Lite, GluNEO Plus), Finetest Lite, Oh'Care blood glucose meters, HbA1c analyzers, cholesterol and lipid meters, liver disease diagnostic systems, immunodiagnostic tests for cardiovascular diseases, cancer (liver, colorectal, prostate), infectious diseases (hepatitis B/C, dengue fever, malaria), sexually transmitted diseases (cervical cancer, syphilis), vitamin D deficiency and pregnancy tests, molecular diagnostics for genomic analysis, respiratory diseases, vector-borne diseases and microbial infections including tuberculosis, as well as health functional foods and supplements; the company serves hospitals, clinics, laboratories and self-testing consumers with user-friendly, rapid diagnostic tools. Founded in 1996 and headquartered in Anyang, Gyeonggi-do, South Korea, Osang Healthcare--formerly Infopia Co., Ltd. until its name change in April 2017--exports to over 110 countries worldwide as an OEM/ODM partner to global firms, with 354 employees focused on chronic and transmissible disease management through cost-effective solutions that reduce healthcare system burdens. In recent strategic developments, the company invested approximately $36 million in U.S.-based Allez Health in 2024, including an initial $22.5 million payment as lead investor in its $60 million Series A+ financing round to support continuous glucose monitoring (CGM) device development, clinical trials and FDA approval, aiming to enhance diabetes management via innovative biosensor technology and leverage Osang's manufacturing and global distribution strengths; Osang is also evolving toward an integrated healthcare platform combining diagnostics, services, data analytics and expansions into health functional foods while launching new IVD products.